Ema approves new storage option for pfizer-biontech vaccine, easing distribution and storage of doses across european union

New york and mainz, germany, march 26 , 2021 — pfizer inc. (nyse: pfe) and biontech se (nasdaq: bntx) announced today that the european medicines agency (ema) approved storage of comirnaty® at -25°c to -15°c for a total of two weeks based on data showing the stability at these temperatures in standard pharmaceutical freezers. the new data is a testament to the companies' ongoing commitment to developing this vaccine further and collecting data in order to support broader and more flexible vaccine distribution and inoculation. with this approval, the comirnaty vials can be stored in all 27 european union (eu) member states at these updated temperatures for a total of two weeks alternatively to the storage at ultra-low temperatures. it marks an important milestone in the vaccine roll-out, as it could allow storage in pharmacies to support vaccinations at local practices/doctors' offices. by enabling more individuals to store and administer the vaccine, the approval will help broaden access, while limiting strain on larger vaccination centers.
BNTX Ratings Summary
BNTX Quant Ranking